Literature DB >> 31207230

HPV16 E7-Driven Epithelial Hyperplasia Promotes Impaired Antigen Presentation and Regulatory T-Cell Development.

Abate Assefa Bashaw1, Siok M Teoh1, Zewen K Tuong1, Graham R Leggatt1, Ian H Frazer2, Janin Chandra1.   

Abstract

Human papillomaviruses infect keratinocytes and can lead to hyperproliferative dysplasia and malignant transformation if not cleared by the immune system. Human papillomavirus has evolved an array of mechanisms to evade and manipulate the immune system to improve replication efficiency and promote persistent infection. We here demonstrate that hyperproliferative skin expressing the high-risk human papillomavirus 16 E7 oncogene as a transgene drives immunomodulation of dendritic cells (DCs), resulting in reduced capacity to take up antigen and prime effector CD4+ T cell responses. The phenotype of DCs in the E7-expressing hyperproliferative skin was not reversible by activation through intradermal immunization. Naïve CD4+ T cells primed by E7-driven hyperproliferative skin acquired FoxP3 expression and an anergic phenotype. DC and T help modulation was dependent on E7-retinoblastoma protein interaction-driven epithelial hyperproliferation, rather than on expression of E7. Inhibition of binding of E7 to retinoblastoma protein, and of consequent epithelial hyperplasia, was associated with normal skin DC phenotype, and T helper type 1 effector responses to immunization were restored. We conclude that human papillomavirus-induced epithelial hyperplasia modulates epithelial DCs and inhibits T helper type 1 immunity while polarizing T-cell differentiation to a regulatory or anergic phenotype.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31207230     DOI: 10.1016/j.jid.2019.03.1162

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.

Authors:  Linda Hertlein; Thomas Kolben; Aurelia Vattai; Nadine Kremer; Sarah Meister; Susanne Beyer; Lucia Keilmann; Anna Hester; Mina Temelkov; Helene Heidegger; Elisa Schmoeckel; Mirjana Kessler; Sven Mahner; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-05       Impact factor: 4.553

Review 2.  Immunotherapy for HPV associated cancer.

Authors:  Ian H Frazer; Janin Chandra
Journal:  Papillomavirus Res       Date:  2019-07-13

3.  Dysregulation of Stemness Pathways in HPV Mediated Cervical Malignant Transformation Identifies Potential Oncotherapy Targets.

Authors:  Megha Budhwani; Samuel W Lukowski; Sandro V Porceddu; Ian H Frazer; Janin Chandra
Journal:  Front Cell Infect Microbiol       Date:  2020-06-25       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.